New drug aims to calm overactive immune system in lupus and related diseases
NCT ID NCT07193810
First seen Oct 31, 2025 · Last updated Apr 28, 2026 · Updated 19 times
Summary
This early-stage trial tests the safety of a new drug, CC312, in 6 adults with lupus, inflammatory myopathies, or systemic sclerosis that have not responded to standard treatments. The study will look for side effects and measure how the drug behaves in the body. It is not expected to cure these conditions, but may help control disease activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Deyang People's Hospital
RECRUITINGDeyang, Sichuan, 618000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.